




Procter & Gamble Australia Pty Ltd
ABN 91 008 396 245
320 Victoria Road
Rydalmere, NSW 2116
PO Box 249
Rydalmere B.C. NSW 1701
+61 2 9684 8444 phone
+61 2 9684 8570 fax



19 May, 2005

Mr. Pio Cesarin Director, Chemical and Non-Prescription Medicines Therapeutic Goods Administration P.O Box 100 Woden, ACT 2606	Dr. Margaret Hartley Director, Office of Chemical Safety, TGA NICNAS P.O Box 58 Sydney, NSW 2001
---	---

Dear Pio and Margaret,

Re: Response to the Recommendations of the Regulation of Products at the Interface between Cosmetics and Therapeutic Goods (Newgreen Review).


Procter & Gamble Australia Pty. Ltd., distributor's of many classes of household goods, cosmetic products and therapeutic products manufactured both in Australia and imported from numerous manufacturing sites internationally have welcomed the opportunity to review and comment on the recommendations made in the Newgreen Review.

We fully support the recommendations proposed by our industry association, ACCORD as presented in the attached submission. Procter & Gamble's product range includes antiperspirants (MUM), anti-dandruff products (Head & Shoulders, Wella Free & Lovely, Pert Antidandruff), Sunscreens (Olay Complete UV Defence Moisture Lotion & Cream) that are currently marketed as well as other products not currently marketed in Australia that include Oral hygiene products and antibacterial skin wash products. The outcome of the Newgreen Review and decisions that will be made as a result will therefore have a direct bearing on our business.

The products included at the cosmetic-drug interface, that are the subject of this review, do not warrant being over regulated. The costs, for example, of maintaining GMP compliance to drug standards for a moisturising-sunscreen product are prohibitive and do not provide any benefit to the end-consumer. International harmonisation of standards and the promotion of free trade will allow us to provide quality products to Australian consumer at the same time as they are developed in other markets.

We seek your urgent consideration and implementation of the proposed additions to the Therapeutic Goods (Excluded Goods) Order as detailed in Attachment 3 of ACCORDS Submission.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Douglas G. Anderson". The signature is fluid and cursive, with the first name being the most prominent.

Douglas G. Anderson

Manager External Relations

Procter & Gamble Australia Pty. Ltd.

Ph: (02) 9684-8303; Fax: (02) 9684-8460; email: anderson.dg@pg.com

L: Newgreen Review/dga19May05